Rehmannioside A Inhibits TRAF6/MAPK Pathway and Improves Psoriasis by Interfering with the Interaction of HaCaT Cells with IL-17A

OBJECTIVE: As a common chronic inflammatory skin disease, psoriasis seriously affects the physical health and psychological well-being of patients. Various clinical treatments for psoriasis have their own drawbacks, so it is important to find effective and safe drugs. Rehmannioside A (ReA) has anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Li-li, Cao, Chun-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519428/
https://www.ncbi.nlm.nih.gov/pubmed/37752969
http://dx.doi.org/10.2147/CCID.S430621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519428/
https://www.ncbi.nlm.nih.gov/pubmed/37752969
http://dx.doi.org/10.2147/CCID.S430621

Ejemplares similares